Reducing Risk of Stroke and DementIa In patientS With COVert cERebrovascular Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Functional and Cognitive scores.
- Who it may be relevant to
- Registry conditions: Covert Cerebrovascular Disease. Basic parameters: from 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Reducing Risk of Stroke and DementIa In patientS With COVert cERebrovascular Disease: a Pilot and Development Study
Overview
The purpose of the DISCOVER study is to pilot acceptable approaches to people with covert cerebrovascular disease (CCD) and their follow-up. This is the first step in designing efficient randomised trials of treatments to reduce the risk of stroke or dementia in people with CCD.
Detailed description
DISCOVER is a prospective cohort involving individuals with covert cerebrovascular disease (CCD) in NHS Lothian. Participants will be recruited through electronic health records and clinician collaborators. Participants will be monitored at 3 and 6 months and where possible 12 months to assess cognitive, functional, and vascular event outcomes.
Interventions
- Other Functional and Cognitive scores
We will collect information about prior neurological symptoms, including prior symptoms suggestive of TIA or stroke, cognitive or motor symptoms, blood pressure and other known vascular risk factors, medicines, frailty, functional status, education, and employment status We will collect a baseline validated function and cognitive score, and take a sample of speech. Speech will be measured at assessment, in collaboration with the NeuroCARE Clinical and Digital Measures Module (22/SS/0010 IRAS No.
Primary outcome measures
- Functional scores [Time frame: At 3, 6 and 12 months following enrolment]
- Cognitive scores [Time frame: At 3, 6 and 12 months following enrolment]
- Speech samples [Time frame: At 3, 6 and 12 months following enrolment]
- Vascular events [Time frame: At 3, 6 and 12 months following enrolment]
Eligibility criteria
Inclusion criteria
- People who, at the time the letter is prepared or are identified by a clinician
- Age ≥ 65 years
- Have no known history of:
- Stroke or TIA
- Dementia
- Parkinson's disease
- Multiple sclerosis
- Metastatic cancer (or non-meningioma brain tumour).
- A CT or MRI scan report ≤5 years before study start date with of one or more of:
- Cerebral small vessel disease
- Deep old ischaemic stroke
- Cortical old ischaemic stroke
Exclusion criteria
- Text of brain scan report unreadable
- Do not consent to take part in study procedures
- Unable to consent
- Unable to communicate by email, letter or telephone through language, speech disability or lack of address
- Unlikely to survive one year past enrolment in judgement of the study investigator
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT06878430 · AC25041 · HIPS/23/02